These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 34195286)
21. Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma. Zhai S; Li Y; Yang Y; Lang W; Liu X; Liu K; Qu J; Zhu L Front Immunol; 2024; 15():1361657. PubMed ID: 39108273 [TBL] [Abstract][Full Text] [Related]
22. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma. Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187 [TBL] [Abstract][Full Text] [Related]
23. The Prognostic Significance of Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587 [TBL] [Abstract][Full Text] [Related]
24. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis. Shi XM; Teng F Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588 [TBL] [Abstract][Full Text] [Related]
25. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis. Wang R; Hu X; Liu X; Bai L; Gu J; Li Q PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762 [TBL] [Abstract][Full Text] [Related]
26. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development. Liu Z; Zhao P J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083 [TBL] [Abstract][Full Text] [Related]
27. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway. Zhang MH; Liu J Bioengineered; 2022 Apr; 13(4):10047-10060. PubMed ID: 35412944 [TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of N Zhu HX; Lu WJ; Zhu WP; Yu S J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346 [TBL] [Abstract][Full Text] [Related]
29. Non-SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma. Sun C; Huang S; Wang H; Xie R; Zhang L; Zhou Q; He X; Ju W Mol Carcinog; 2019 Dec; 58(12):2266-2275. PubMed ID: 31523845 [TBL] [Abstract][Full Text] [Related]
30. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target. Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L Front Immunol; 2023; 14():1158360. PubMed ID: 37483608 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma. He D; Zhang X; Tu J Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904 [TBL] [Abstract][Full Text] [Related]
32. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma. Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157 [TBL] [Abstract][Full Text] [Related]
33. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591 [TBL] [Abstract][Full Text] [Related]
34. A novel prognostic biomarker: Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536 [TBL] [Abstract][Full Text] [Related]
35. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Chen J; Yang J; Xu Q; Wang Z; Wu J; Pan L; Huang K; Wang C Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33605411 [TBL] [Abstract][Full Text] [Related]
36. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Cui XH; Peng QJ; Li RZ; Lyu XJ; Zhu CF; Qin XH J Cell Mol Med; 2021 Dec; 25(24):11097-11112. PubMed ID: 34741389 [TBL] [Abstract][Full Text] [Related]
37. FBX8 Acts as an Invasion and Metastasis Suppressor and Correlates with Poor Survival in Hepatocellular Carcinoma. Wang F; Qiao Y; Yu J; Ren X; Wang J; Ding Y; Zhang X; Ma W; Ding Y; Liang L PLoS One; 2013; 8(6):e65495. PubMed ID: 23826080 [TBL] [Abstract][Full Text] [Related]
38. Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks. Yu X; Zhang J; Yang R; Li C Biomed Res Int; 2020; 2020():8579651. PubMed ID: 33299877 [TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma. Wang H; Wang H; Cui W; Zhang Q; Li J; Zhang Q Diagn Pathol; 2021 Jun; 16(1):51. PubMed ID: 34116691 [TBL] [Abstract][Full Text] [Related]
40. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis. Zhang JN; Wei F; Lei LH; Yang Y; Yang Y; Zhou WP Bioengineered; 2021 Dec; 12(2):11728-11739. PubMed ID: 34784846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]